These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 15651756)

  • 1. Health-related quality of life in HIV patients switching to twice-daily indinavir/ritonavir regimen or continuing with three-times-daily indinavir-based therapy.
    Badía X; Podzamczer D; Moral I; Roset M; Arnaiz JA; Loncà M; Casiró A; Rosón B; Gatell JM;
    Antivir Ther; 2004 Dec; 9(6):979-85. PubMed ID: 15651756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A once-daily HAART regimen containing indinavir + ritonavir plus one or two nucleoside reverse transcriptase inhibitors (PIPO study).
    Burger DM; Aarnoutse RE; Dieleman JP; Gyssens IC; Nouwen J; de Marie S; Koopmans PP; Stek M; van der Ende ME
    Antivir Ther; 2003 Oct; 8(5):455-61. PubMed ID: 14640393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
    Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
    Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indinavir/ritonavir-based therapy in HIV-1-infected antiretroviral therapy-naive patients: comparison of 800/100 mg and 400/100 mg twice daily.
    Konopnicki D; De Wit S; Poll B; Crommentuyn K; Huitema A; Clumeck N
    HIV Med; 2005 Jan; 6(1):1-6. PubMed ID: 15670245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
    HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109).
    Launay O; Duval X; Dalban C; Descamps D; Peytavin G; Certain A; Mouajjah S; Ralaimazava P; Verdon R; Costagliola D; Clavel F;
    Antivir Ther; 2006; 11(7):889-99. PubMed ID: 17302251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using ritonavir with indinavir in cases of virologic failure.
    TreatmentUpdate; 2001; 12(12):7. PubMed ID: 11570095
    [No Abstract]   [Full Text] [Related]  

  • 8. Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005).
    Boyd MA; Srasuebkul P; Khongphattanayothin M; Ruxrungtham K; Hassink EA; Duncombe CJ; Ubolyam S; Burger DM; Reiss P; Stek M; Lange J; Cooper DA; Phanuphak P
    Antivir Ther; 2006; 11(2):223-32. PubMed ID: 16640103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir.
    Aarnoutse RE; Wasmuth JC; Fätkenheuer G; Schneider K; Schmitz K; de Boo TM; Reiss P; Hekster YA; Burger DM; Rockstroh JK
    Antivir Ther; 2003 Aug; 8(4):309-14. PubMed ID: 14518700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of indinavir on the quality of life in patients with advanced HIV infection treated with zidovudine and lamivudine.
    Coplan PM; Cook JR; Carides GW; Heyse JF; Wu AW; Hammer SM; Nguyen BY; Meibohm AR; DiNubile MJ;
    Clin Infect Dis; 2004 Aug; 39(3):426-33. PubMed ID: 15307012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients.
    Boyd M; Mootsikapun P; Burger D; Chuenyam T; Ubolyam S; Mahanontharit A; Sangkote J; Bunyaprawit P; Horsakulchai M; Lange J; Cooper D; Phanuphak P; Ruxrungtham K
    Antivir Ther; 2005; 10(2):301-7. PubMed ID: 15865224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of lopinavir/ritonavir monotherapy on quality of life and self-reported symptoms among antiretroviral-naive patients: results of the MONARK trial.
    Spire B; Marcellin F; Cohen-Codar I; Flandre P; Boue F; Dellamonica P; Raffi F; Norton M; Van Philippe N; Delfraissy JF
    Antivir Ther; 2008; 13(4):591-9. PubMed ID: 18672538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ritonavir/saquinavir plus one nucleoside reverse transcriptase inhibitor (NRTI) versus indinavir plus two NRTIs in protease inhibitor-naive HIV-1-infected adults (IRIS study).
    Florence E; Dreezen C; Desmet P; Smets E; Fransen K; Vandercam B; Pelgrom J; Clumeck N; Colebunder R
    Antivir Ther; 2001 Dec; 6(4):255-62. PubMed ID: 11878407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals.
    Duvivier C; Myrto A; Marcelin AG; Ghosn J; Ait-Mohand H; Schneider L; Agher R; Bricaire F; Costagliola D; Calvez V; Peytavin G; Katlama C
    Antivir Ther; 2003 Dec; 8(6):603-9. PubMed ID: 14760894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Open-label study of a twice-daily indinavir 800-mg/ritonavir 200-mg regimen in HIV-infected adults failing a protease inhibitor regimen.
    Katner HP; Paar DP; Nadler JP; Jensen EH; Wilson HM; Finn TS; Petruschke RA; Zeldin RK
    J Acquir Immune Defic Syndr; 2002 Dec; 31(5):483-7. PubMed ID: 12473836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switch from ritonavir to indinavir in combination therapy for HIV-1-infected children.
    Pelton SI; Stanley K; Yogev R; Fletcher CV; McIntosh K; Wiznia A; Nachman S;
    Clin Infect Dis; 2005 Apr; 40(8):1181-7. PubMed ID: 15791520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The long-term pharmacokinetics and safety of adding low-dose ritonavir to a nelfinavir 1,250 mg twice-daily regimen in HIV-infected patients.
    Justesen US; Hansen IM; Andersen AB; Klitgaard NA; Black FT; Gerstoft J; Mathiesen LR; Pedersen C
    HIV Med; 2005 Sep; 6(5):334-40. PubMed ID: 16156881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ritonavir and indinavir one year later.
    TreatmentUpdate; 2001; 12(12):6-7. PubMed ID: 11570094
    [No Abstract]   [Full Text] [Related]  

  • 19. Simplifying drug regimens.
    HIV Hotline; 1998 Mar; 8(1):11. PubMed ID: 11365353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The choice of HIV protease inhibitor: indinavir is currently the best option.
    Prescrire Int; 1999 Apr; 8(40):55-60. PubMed ID: 10848067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.